Tardive dyskinesia

Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders

Retrieved on: 
Monday, October 1, 2018
Neurological disorders, Tardive dyskinesia, Medicine, Neurocrine Biosciences, RTT, Health, Disability, Tardive, Valbenazine, Neurocrine, Dyskinesia

"In our long-term studies with INGREZZA, patients with tardive dyskinesia have shown improvement across body regions, including the face, torso and extremities.

Key Points: 
  • "In our long-term studies with INGREZZA, patients with tardive dyskinesia have shown improvement across body regions, including the face, torso and extremities.
  • We look forward to presenting these new analyses to help healthcare providers further understand how INGREZZA can help patients suffering from tardive dyskinesia."
  • Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders.
  • Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.

Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics

Retrieved on: 
Tuesday, May 8, 2018
Neurological disorders, RTT, Neurology, Medicine, Psychiatry, Syndromes, Tardive dyskinesia, Antipsychotic, Dyskinesia, Psychosis, Typical antipsychotic, Pleurothotonus

Results from the RE-KINECT study showed that nearly 28 percent of patients treated with an antipsychotic had clinician-confirmed possible TD.

Key Points: 
  • Results from the RE-KINECT study showed that nearly 28 percent of patients treated with an antipsychotic had clinician-confirmed possible TD.
  • Over half of patients with clinician-confirmed possible TD were affected by uncontrollable movements in two or more body regions.
  • "It is important that psychiatrists and neurologists take these findings into consideration when managing patients treated with antipsychotic medications.
  • Now that we have approved treatment options for tardive dyskinesia, it is important to proactively screen patients for the symptoms of tardive dyskinesia and diagnose patients living with this condition."

Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting

Retrieved on: 
Wednesday, May 2, 2018
Psychiatry, Abnormal psychology, Psychopathology, RTT, Tardive dyskinesia, Schizophrenia, Neurocrine Biosciences, Schizoaffective disorder, Antipsychotic, Valbenazine, Psychosis, American Psychiatric Association

SAN DIEGO, May 2, 2018 /PRNewswire/ --Neurocrine Biosciences Inc. (NASDAQ: NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD).

Key Points: 
  • SAN DIEGO, May 2, 2018 /PRNewswire/ --Neurocrine Biosciences Inc. (NASDAQ: NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD).
  • This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated with antipsychotic medications.
  • Neurocrine will also present new data from the KINECT 4 study on long-term treatment with INGREZZA (valbenazine) capsules in participants with schizophrenia/schizoaffective disorder or mood disorder.
  • These new data will be presented at the American Psychiatric Association (APA) Annual Meeting in New York City, May 5-9, 2018.